BridgeBio Oncology Therapeutics
Latest round
- Series B
Last raised
- May 2024
Total raised
- $200M
Investors
- 11
About BridgeBio Oncology Therapeutics
Based in the US, BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of small molecule therapeutics targeting RAS and PI3K malignancies. The company’s pipeline includes BBO-8520, a direct inhibitor of KRASG12C, a genetic mutation implicated in non-small cell lung cancer. The firm enrols patients in the ONKORAS-101 trial for individuals with KRASG12C mutant tumors. The firm is also developing BBO-10203, a PI3Ka: RAS breaker designed to disrupt the interaction between RAS and PI3Ka, thereby inhibiting tumor growth while mitigating the risk of hyperglycemia. In addition, BridgeBio's pipeline also encompasses BBO-11818, a pan-KRAS inhibitor targeting both the active and inactive states of KRASG12X.
Who invested in BridgeBio Oncology Therapeutics
11 investors across 1 round
See all investors in BridgeBio Oncology Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
May 2, 2024
Amount
$200M
Investors
Questions about BridgeBio Oncology Therapeutics
Who invested in BridgeBio Oncology Therapeutics?
BridgeBio Oncology Therapeutics has 11 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BridgeBio Oncology Therapeutics raised?
BridgeBio Oncology Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did BridgeBio Oncology Therapeutics last raise money?
BridgeBio Oncology Therapeutics's most recent round on record is a Series B, in May 2024.
What does BridgeBio Oncology Therapeutics do?
Based in the US, BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of small molecule therapeutics targeting RAS and PI3K malignancies.
Where is BridgeBio Oncology Therapeutics headquartered?
BridgeBio Oncology Therapeutics is headquartered in Palo Alto, US.
Which VCs invest in companies like BridgeBio Oncology Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at BridgeBio Oncology Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like BridgeBio Oncology Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.